{"count":2329,"next":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=2000&ordering=-begin_planned","previous":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1960&ordering=-begin_planned","results":[{"id":2151,"title":{"de":"Entwicklung eines praktikablen Werkzeugs für die Bewertung und Implementierung evidenzbasierter Leitlinien in Kooperation mit den Krankenhäusern in der Steiermark","en":"Entwicklung eines praktikablen Werkzeugs für die Bewertung und Implementierung evidenzbasierter Leitlinien in Kooperation mit den Krankenhäusern in der Steiermark"},"short":"EVIDENZBASIERTE LEITLINIEN","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-05-01T02:00:00+02:00","begin_effective":"2009-05-01T02:00:00+02:00","end_planned":"2011-04-30T02:00:00+02:00","end_effective":"2011-04-30T02:00:00+02:00","assignment":"2010-03-04T12:31:15+01:00","program":null,"subprogram":null,"organization":14026,"category":10,"type":10,"partner_function":4,"manager":51098,"contact":51098,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2151-51098-10"]},{"id":1908,"title":{"de":"GATiB II - Subprojekt 1","en":"GATiB II - Subproject 1"},"short":"GATiB II - Subprojekt 1","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-05-01T02:00:00+02:00","begin_effective":"2009-10-01T02:00:00+02:00","end_planned":"2012-04-30T02:00:00+02:00","end_effective":"2012-09-30T02:00:00+02:00","assignment":"2009-09-03T17:01:48+02:00","program":73,"subprogram":null,"organization":14020,"category":10,"type":10,"partner_function":2,"manager":51663,"contact":51663,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[152],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1908-51663-10"]},{"id":1882,"title":{"de":"Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer","en":"Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer"},"short":"CHEMOTHERAP_BREAST CANCER","url":null,"abstract":{"de":"Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis.","en":"Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis."},"begin_planned":"2009-05-01T02:00:00+02:00","begin_effective":"2009-05-01T02:00:00+02:00","end_planned":"2009-09-30T02:00:00+02:00","end_effective":"2010-09-30T02:00:00+02:00","assignment":"2009-08-03T14:52:33+02:00","program":null,"subprogram":null,"organization":14085,"category":10,"type":10,"partner_function":4,"manager":58814,"contact":58814,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[457],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1882-58814-10"]},{"id":1940,"title":{"de":"Altered prostaglandin receptor function in patients with aspirin intolerance","en":"Altered prostaglandin receptor function in patients with aspirin intolerance"},"short":"Prostaglandin receptor function","url":null,"abstract":{"de":"Prostaglandin E2 (PGE2) limitiert in der Lunge immunologische und entzündliche Prozesse. Eosinophile Granulozyten spielen eine entscheidende Rolle bei der Pathogenese von Asthma bronchiale. Etwa 10% der Asthmapatienten vertragen keine Analgetika vom Typ der nichtsteroidalen Antirheumatika (z.B. Aspirin). Daher ist eine effektive Schmerz- und Entzündungstherapie bei diesen Patienten schwierig. Wir konnten zeigen, dass PGE2 hemmende Effekte an eosinophilen Granulozyten hat. Die Effekte von PGE2 werden durch vier Rezeptoren vermittelt. Wir untersuchen, inwieweit die Wirkungen von PGE2 auf Eosinophile von Patienten mit Aspirin-Unverträglichkeit verändert sind und welche Rolle die PGE2 Rezeptoren spielen. Als Vergleich dienen gesunde Probanden, allergische Patienten ohne Asthma und Asthmatiker ohne Aspirin-Unverträglichkeit. Diese Studie soll das Verständnis der Rolle von PGE2 bei Asthma und Aspirin-Unverträglichkeit erweitern, und möglicherweise neue therapeutische Optionen eröffen.","en":"Prostaglandin E2 (PGE2) limitiert in der Lunge immunologische und entzündliche Prozesse. Eosinophile Granulozyten spielen eine entscheidende Rolle bei der Pathogenese von Asthma bronchiale. Etwa 10% der Asthmapatienten vertragen keine Analgetika vom Typ der nichtsteroidalen Antirheumatika (z.B. Aspirin). Daher ist eine effektive Schmerz- und Entzündungstherapie bei diesen Patienten schwierig. Wir konnten zeigen, dass PGE2 hemmende Effekte an eosinophilen Granulozyten hat. Die Effekte von PGE2 werden durch vier Rezeptoren vermittelt. Wir untersuchen, inwieweit die Wirkungen von PGE2 auf Eosinophile von Patienten mit Aspirin-Unverträglichkeit verändert sind und welche Rolle die PGE2 Rezeptoren spielen. Als Vergleich dienen gesunde Probanden, allergische Patienten ohne Asthma und Asthmatiker ohne Aspirin-Unverträglichkeit. Diese Studie soll das Verständnis der Rolle von PGE2 bei Asthma und Aspirin-Unverträglichkeit erweitern, und möglicherweise neue therapeutische Optionen eröffen."},"begin_planned":"2009-04-01T02:00:00+02:00","begin_effective":"2010-01-01T01:00:00+01:00","end_planned":"2011-03-31T02:00:00+02:00","end_effective":"2013-09-30T02:00:00+02:00","assignment":"2009-10-01T18:22:11+02:00","program":79,"subprogram":null,"organization":14022,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2008,"title":{"de":"Ganganalysen bei Kindern mit Morbus Perthes","en":"Ganganalysen bei Kindern mit Morbus Perthes"},"short":"Morbus Perthes","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-04-01T02:00:00+02:00","begin_effective":"2009-04-01T02:00:00+02:00","end_planned":"2009-08-31T02:00:00+02:00","end_effective":"2012-07-31T02:00:00+02:00","assignment":"2009-12-04T11:57:57+01:00","program":null,"subprogram":"Land Steiermark Abteilung 3","organization":14049,"category":10,"type":10,"partner_function":4,"manager":65038,"contact":65038,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2008-65038-10"]},{"id":2391,"title":{"de":"Einfluss der Knochenentnahmetechnik auf die Osteoblastenaktivität","en":"Effect of Bone Harvesting Methods to the Osteoblast activity"},"short":"KNOCHENENTNAHME_OSTEOBLAST","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-04-01T02:00:00+02:00","begin_effective":"2011-01-26T01:00:00+01:00","end_planned":"2010-10-01T02:00:00+02:00","end_effective":"2017-12-31T01:00:00+01:00","assignment":"2011-02-04T09:47:14+01:00","program":null,"subprogram":null,"organization":14057,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":4,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":1732,"title":{"de":"Zerebrale und peripher-muskuläre Gewebssättigung unmittelbar nach der Geburt [Postpartale zerebrale und periphere Oxygenierung bei reifen Neugeborenen und Frühgeborenen]","en":"Transition after birth: cerebral and peripheral muscle oxygenation in term and preterm neonates"},"short":"Oxygenierung","url":null,"abstract":{"de":"Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring.","en":"Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring."},"begin_planned":"2009-04-01T02:00:00+02:00","begin_effective":"2009-04-01T02:00:00+02:00","end_planned":"2011-03-31T02:00:00+02:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-01-19T12:54:11+01:00","program":79,"subprogram":null,"organization":14094,"category":10,"type":10,"partner_function":4,"manager":50907,"contact":50907,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1732-50907-10"]},{"id":2796,"title":{"de":"Anschaffung eines ultrahochauflösenden Massenspektrometrie Systems als Lipidomics und Proteomics Plattform an der Medizinischen Universität Graz. ","en":"Anschaffung eines ultrahochauflösenden Massenspektrometrie Systems als Lipidomics und Proteomics Plattform an der Medizinischen Universität Graz. "},"short":"EFRE- Massenspektometrie","url":null,"abstract":{"de":"Ziel dieses Projektes ist die Anschaffung eines ultrahochauflösenden Massenspektrometers zur qualitativen und quantitativen Bestimmung von Lipiden und im Lipidstoffwechsel aktiven Enzymen, welche in Krankheitsbildern wie Metabolisches Syndrom, chronische Entzündung, Diabetes oder Atherosklerose eine entscheidende Rolle spielen. Der Vorteil von Ultrahochauflösung liegt in der daraus berechenbaren exakten Masse über welche die Identifizierungssicherheit von Lipiden und Proteinen enorm gesteigert werden kann. Als zusätzliche Selektivitätskriterien sollen Fragmentspektren und chromatographische Retentionszeiten herangezogen werden können um über Polarität und Struktur des Moleküls auf dessen Identität schließen zu können. Durch das Zusammenspiel dieser oben genannten technischen Parameter wird es möglich sein die Anzahl von bestimmbaren Lipiden und Proteinen pro Probe deutlich zu steigern. Dadurch sind wichtige Signalmoleküle die in geringsten Mengen im Organismus vorkommen und deshalb für die molekulare Grundlagenforschung von ganz besonderem Interesse sind auch erfassbar.\r\nDie Lipidforschung in Graz und an der MUG genießt Weltruf und ist ein verbindendes Element zwischen allen Grazer akademischen Institutionen. Durch den technologischen Fortschritt im Bereich der Massenspektrometrie wurde es in der letzten Dekade möglich immer detailiertere Informationen über das molekulare Geschehen in biologischen Systemen auf Ebene von Lipiden und Proteinen zu gewinnen. Die daraus entstandenen Begriffe Lipidomics und Proteomics sind die deskriptive Erforschung der Gesamtheit aller Lipide und Proteine in einem definierten biologischen System. Die Basis dieser neuen ‚omics’ Wissenschaften sind massenspektrometrische Systeme welche im Zuge des technologischen Fortschritts immer empfindlicher und schneller (High Throughput) werden, sowie eine immer höhere Massenauflösung bieten. Diese Faktoren sind die Grundlage um möglichst viele Lipide und Proteine in kurzer Zeit mit hoher Treffsicherheit bestimmen zu können, vor allem auch jene Spezies welche zwar in äußerst geringer Konzentration in zellulären Systemen vorkommen, aber häufig sehr großen Einfluss auf Signalübertragungsprozesse haben. \r\nIm Bereich der Lipide geht die Schätzung natürlich vorkommender molekularer Spezies auf weit über 100.000 wovon bisher knapp 10.000 beschrieben und in Datenbanken erfasst sind. Für die Identifizierung und Charakterisierung zusätzlicher Substanzen ist ultrahochauflösende Massenspektrometrie aufgrund der mit dieser Eigenschaft einhergehenden hohen Konfidenz mittlerweile ein unverzichtbares Werkzeug geworden. Aber auch die Quantifizierung des bereits in Datenbanken erfassten Lipidoms in allen seinen Einzelbausteinen ist für Forschungsprojekte der MUG im 21. Jahrhundert die deskriptive Grundlage auf der Hypothesen über zelluläre Mechanismen des Fettstoffwechsels aufgebaut und in weiterer Folge verifiziert oder auch falsifiziert werden. \r\nMit dem in Graz entwickelten System der Activity based Proteomics ist es möglich am Lipidstoffwechsel beteiligte Enzyme (Lipasen) über Fluoreszenzlabeling und Massenspektrometrie zielgenau zu identifizieren. Da viele Lipasen in geringsten Mengen vorkommen ist es auch hier essentiell, möglichst hohe Identitätssicherheit mit maximaler analytischer Empfindlichkeit zu kombinieren. Mit diesem System wird es möglich sein auch in Zukunft neue regulatorische Schlüsselstellen des Lipidstoffwechsels sichtbar und der medizinischen Weiterverwertung zugänglich zu machen.\r\n\r\n","en":"Ziel dieses Projektes ist die Anschaffung eines ultrahochauflösenden Massenspektrometers zur qualitativen und quantitativen Bestimmung von Lipiden und im Lipidstoffwechsel aktiven Enzymen, welche in Krankheitsbildern wie Metabolisches Syndrom, chronische Entzündung, Diabetes oder Atherosklerose eine entscheidende Rolle spielen. Der Vorteil von Ultrahochauflösung liegt in der daraus berechenbaren exakten Masse über welche die Identifizierungssicherheit von Lipiden und Proteinen enorm gesteigert werden kann. Als zusätzliche Selektivitätskriterien sollen Fragmentspektren und chromatographische Retentionszeiten herangezogen werden können um über Polarität und Struktur des Moleküls auf dessen Identität schließen zu können. Durch das Zusammenspiel dieser oben genannten technischen Parameter wird es möglich sein die Anzahl von bestimmbaren Lipiden und Proteinen pro Probe deutlich zu steigern. Dadurch sind wichtige Signalmoleküle die in geringsten Mengen im Organismus vorkommen und deshalb für die molekulare Grundlagenforschung von ganz besonderem Interesse sind auch erfassbar.\r\nDie Lipidforschung in Graz und an der MUG genießt Weltruf und ist ein verbindendes Element zwischen allen Grazer akademischen Institutionen. Durch den technologischen Fortschritt im Bereich der Massenspektrometrie wurde es in der letzten Dekade möglich immer detailiertere Informationen über das molekulare Geschehen in biologischen Systemen auf Ebene von Lipiden und Proteinen zu gewinnen. Die daraus entstandenen Begriffe Lipidomics und Proteomics sind die deskriptive Erforschung der Gesamtheit aller Lipide und Proteine in einem definierten biologischen System. Die Basis dieser neuen ‚omics’ Wissenschaften sind massenspektrometrische Systeme welche im Zuge des technologischen Fortschritts immer empfindlicher und schneller (High Throughput) werden, sowie eine immer höhere Massenauflösung bieten. Diese Faktoren sind die Grundlage um möglichst viele Lipide und Proteine in kurzer Zeit mit hoher Treffsicherheit bestimmen zu können, vor allem auch jene Spezies welche zwar in äußerst geringer Konzentration in zellulären Systemen vorkommen, aber häufig sehr großen Einfluss auf Signalübertragungsprozesse haben. \r\nIm Bereich der Lipide geht die Schätzung natürlich vorkommender molekularer Spezies auf weit über 100.000 wovon bisher knapp 10.000 beschrieben und in Datenbanken erfasst sind. Für die Identifizierung und Charakterisierung zusätzlicher Substanzen ist ultrahochauflösende Massenspektrometrie aufgrund der mit dieser Eigenschaft einhergehenden hohen Konfidenz mittlerweile ein unverzichtbares Werkzeug geworden. Aber auch die Quantifizierung des bereits in Datenbanken erfassten Lipidoms in allen seinen Einzelbausteinen ist für Forschungsprojekte der MUG im 21. Jahrhundert die deskriptive Grundlage auf der Hypothesen über zelluläre Mechanismen des Fettstoffwechsels aufgebaut und in weiterer Folge verifiziert oder auch falsifiziert werden. \r\nMit dem in Graz entwickelten System der Activity based Proteomics ist es möglich am Lipidstoffwechsel beteiligte Enzyme (Lipasen) über Fluoreszenzlabeling und Massenspektrometrie zielgenau zu identifizieren. Da viele Lipasen in geringsten Mengen vorkommen ist es auch hier essentiell, möglichst hohe Identitätssicherheit mit maximaler analytischer Empfindlichkeit zu kombinieren. Mit diesem System wird es möglich sein auch in Zukunft neue regulatorische Schlüsselstellen des Lipidstoffwechsels sichtbar und der medizinischen Weiterverwertung zugänglich zu machen.\r\n\r\n"},"begin_planned":"2009-03-29T01:00:00+01:00","begin_effective":"2009-03-29T01:00:00+01:00","end_planned":"2011-03-31T02:00:00+02:00","end_effective":"2011-03-31T02:00:00+02:00","assignment":null,"program":null,"subprogram":"EFRE","organization":17225,"category":10,"type":10,"partner_function":4,"manager":58794,"contact":58794,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[10,135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2796-58794-10"]},{"id":2661,"title":{"de":"Doktoratskolleg \"Metabolische und Kardiovaskuläre Erkrankungen\"","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14020,"category":10,"type":10,"partner_function":2,"manager":51663,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2661-51663-10"]},{"id":2330,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" (1. Förderperiode)","en":"Doktoratskolleg \"Metabolic and cardiovascular disease\" (1. funding periode)"},"short":"DK-MCD","url":null,"abstract":{"de":"Das Doktoratskolleg-Plus (DK-Plus) \"Metabolische und kardiovaskuläre Erkrankungen\" ist ein von der Medizinischen Universität Graz getragenes Ausbildungsprogramm. Fünfzehn WissenschaftlerInnen der drei Grazer Universitäten (Medizinische Universität, Universität Graz, Technische Universität) entwickelten ein multidisziplinäres Graduierten-Ausbildungs-programm, das sich mit molekularen Mechanismen und zellulären Funktionen in der Pathogenese metabolischer und kardiovaskulärer Erkrankungen beschäftigen. Die thematische Vernetzung dieses DK-Plus sichert einen regen Austausch von Wissen/ Methodik innerhalb der biomedizinischen Forschung, um den Fortschritt in wissenschaftlichen Konzepten zu gewährleisten. Gleichzeitig ist das DK-Plus facettenreich genug um den Studierenden auch einen Blick über den unmittelbaren Fokus ihres eigenen wissenschaftlichen Bereichs hinaus zu ermöglichen. \r\nUm ein stimulierendes Forschungsumfeld anbieten zu können wurden die Teilnehmer auf der Basis exzellenter Forschung (nachgewiesen durch Publikationen und Drittmittel-Förderung) sowie exzellenter Lehre ausgewählt. Der Lehrkörper repräsentiert eine ausgewogene Mischung von etablierten und jüngeren WissenschaftlerInnen, wobei auch Frauen eine tragende Rolle als Gruppenleiterinnen zukommt. Die meisten WissenschaftlerInnen sind in lokale Forschungsnetzwerke wie den SFB \"Lipotoxizität\" und GEN-AU Projekte \"Genomik lipid-assoziierter Erkrankungen\", \"Bioinformatik Integrations-netzwerk\" und \"Genom Österreich Gewebebank\" involviert, die die Kooperation und Kommunikation zwischen den einzelnen Labors gewährleisten. Die vorhandene Infrastruktur bietet modernste Ausstattung, wobei alle beteiligten WissenschaftlerInnen ihre technische Expertise als einen wesentlichen Beitrag zu diesem Netzwerk ansehen. Weiters sind alle Beteiligten in der Betreuung von Doktoratsstudierenden versiert. Dieses DK-Plus stellt eine ideale Ergänzung zu dem bereits existierenden biotechnologisch-orientierten DK-Plus \"Molekulare Enzymologie\" dar und schließt eine Lücke in der Doktorandenausbildung der biomedizinischen Forschung in Graz. \r\nDas DK-Plus \"Metabolische und kardiovaskuläre Erkrankungen\" ist ein anspruchsvolles Ausbildungsprogramm für Doktoratsstudierende: es inkludiert (i) einen multidisziplinären Lehrkörper, der Themen von Grundlagenforschung bis zu klinischen Aspekten unterichtet (ii) einen breiten translatorischen Ansatz, (iii) eine leistungsbezogene Auswahl der Studierenden, (iv) eine gemeinsame Betreuung durch Doktoratskommittees, (v) einen (inter)nationalen Austausch von Studierenden, und (vi) eine Ausbildung in forschungsbezogenen Zusatzqualifikationen. Das DK-Plus ist attraktiv für hochmotivierte Studierende und wird diesen eine Karriere in Gebieten von wachsender Bedeutung für Gesundheit und Gesellschaft wie Biowissenschaften und Biomedizin ermöglichen.\r\n","en":"The doctoral program \"Metabolic and Cardiovascular Disease\" (DK-MCD) is an educational program hosted by the Medical University of Graz, Austria. Fifteen researchers from three universities (Medical University of Graz, University of Graz, Graz University of Technology) have developed a multidisciplinary graduate training program to investigate the molecular mechanisms and cellular functions involved in the pathogenesis of metabolic and cardiovascular disease. The thematic diversity of the DK-MCD ensures broad exposure of the participating students to important issues in biomedicine. Research topics were selected to maximize exchange within the consortium concerning technical proficiency and advances in biomedical research. Importantly, the DK-MCD is sufficiently diverse to encourage students to look beyond the focus of their own research. \r\nTo provide a stimulating and provocative research environment, the DK-MCD faculty was chosen for their excellence in research as indicated by publishing and funding records as well as their excellence in teaching. The faculty represents a well-balanced combination of established and junior scientists. Especially in the latter group female researchers have a prominent role. All DK-MCD faculty members are involved in local, national and international research networks. Thus, the DK-MCD will be embedded in an established inter-laboratory cooperation and communication environment. Faculty members contribute to this initiative by their scientific background in both basic research and clinical medicine. Their technical expertise is complemented by excellent infrastructure and state-of-the-art technology for biomedical research.\r\nThe DK-MCD faculty is well experienced in training doctoral students. The biomedically-oriented DK-MCD curriculum complements the existing biotechnology-oriented DK-Plus \"Molecular Enzymology\". Therefore, our initiative fills an existing gap and covers essential educational aspects for life sciences not yet available in Graz. \r\nThe DK-MCD provides a challenging PhD education program which is unique because it (i) comprises a multidisciplinary faculty from three local universities, (ii) requires (inter)national student exchange and (iii) covers major topics in metabolic and cardiovascular disease from basic research to clinical aspects in a translational approach. We are confident that the DK-MCD will attract highly motivated and dedicated students seeking knowledge and skills that will enable them to pursue careers in areas of growing importance for health and society.\r\n"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14020,"category":10,"type":10,"partner_function":3,"manager":51691,"contact":51691,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2330-50903-12","2330-57409-12","2330-89734-12","2330-51691-10"]},{"id":1821,"title":{"de":"Nano-Health: Nano-Plaque-Extension","en":"Nano-Health: Nano-Plaque-Extension"},"short":"Nano-Plaque-Extension","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-01-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T13:05:25+02:00","program":null,"subprogram":"Nano-Health Verlängerung","organization":14028,"category":10,"type":10,"partner_function":2,"manager":52854,"contact":52854,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1821-52854-10"]},{"id":2659,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14021,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2663,"title":{"de":"Doktoratskolleg \"Metabolische und Kardiovaskuläre Erkrankungen\"","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":"Projekt 1 erarbeit die subuellulären Mechanismen getriggerter Arrhythmien unter besonderer Berücksichtigung eines gestörten Funktion des Ryanodin-Rezeptors des sarkoplasmatischen Retikulums.\r\n\r\nProjekt 2 untersucht den Einfluss von milder Hypothermie auf Hämodynamik, zelluläre und subzelluläre Funktion im Schockmodell und Sepsismodell.","en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2009-12-18T01:00:00+01:00","program":66,"subprogram":null,"organization":14083,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2660,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14081,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2660-66436-12"]},{"id":2655,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":2,"manager":51860,"contact":51860,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2655-51860-10"]},{"id":1819,"title":{"de":"Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo","en":"Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo"},"short":"Nano-Health: 4D Imaging of Stem Cells","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T11:50:29+02:00","program":null,"subprogram":"Nano-Health","organization":14082,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1819-50747-12"]},{"id":2656,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":2,"manager":51904,"contact":51904,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2656-51904-10"]},{"id":2658,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":"Identifying the molecular and regulatory mechanisms of HDL metabolism at the BBB will help to uncover the protective role of HDL against lipid-related neurodegenerative diseases such as Alzheimer’s disease.\r\nDuring the first funding period of the DK-Plus, students in U. Panzenboeck’s group will characterize phospholipid transfer protein function at the BBB to test the hypothesis if PLTP expression in cerebrovascular endothelial cells (EC) can be modulated and is involved in HDL remodelling and in lipid transport between the brain and the circulation. In a second show case the student will investigate the capacity of HDL particles to mediate/facilitate bidirectional oxysterol transport across the BBB and will aim to identify oxysterol transporting proteins in brain capillary EC. \r\n"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14014,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2654,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg \"Metabolic disorders and cellular dysfunction\" "},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":"Proteomic investigation of lipotoxicity in tumor-associated cachexia\r\nObjective: To elucidate possible causes and effects of tumor-induced lipotoxicity on the proteome level.\r\nCachexia is commonly recognized as progressive weight loss with depletion of host reserves of adipose tissue and skeletal muscle and associated with cancers of gastrointestinal tract and lung. Survival of cancer patients is directly related to weight loss. The reduction of food intake alone is unable to explain the metabolic changes seen in cachexia. Moreover, loss of muscle and adipose tissue precedes the fall in food intake. The causes and mechanisms responsible for tumor-associated cachexia remain to be unravelled. Preliminary data generated in Gerald Hoefler´s laboratory demonstrate an involvement of adipose triglyceride lipase (ATGL) in the development of cachexia. While implantation of Lewis lung carcinoma cells into wild-type mice resulted in a vast reduction of gastrognemious muscle and white adipose tissue and a minor reduction in heart weight, none of these effects were seen in ATGL-ko mice.\r\nTissues from cachexia mouse models will be obtained from G. Hoefler. Proteomes from gastrognemious muscle, adipose tissues, liver, heart and spleen of wild-type and ATGL-ko mice with and without transplanted tumor will be profiled with respect to protein abundance by differential gelelectrophoresis (DIGE) and/or isotope labeling, liquid chromatography and mass spectrometry (LC-MS). Phosphoproteomics of selected cellular fractions will be performed using immobilized metal affinity chromatography (IMAC, TiO2) for phosphopeptide enrichment, isotopic labeling for quantification, LC-MS with phospho-group neutral loss scanning and database search for phospho-group modifications. Differences in lipase and esterase activities will be assessed by activity-based proteomics employing suitable probes (developed by the applicant) and by standard proteomic techniques.\r\n\r\nRegulatory and compensatory mechanisms of lipolytic pathways\r\nBackground: While the lipolytic proteome of mouse adipose tissue has been identified (3), many of the underlying regulatory processes remain unknown. Therefore, regulatory and compensatory mechanisms of lipolytic pathways as well as changes in the overall proteome will be determined upon shut down of individual pathways (e.g. in hormone sensitive lipase (HSL)- and ATGL-deficient mice). The phenotypes of the respective mouse models differ greatly with regard to body weight, lipid accumulation, fertility and organ specific defects. Thus, large effects are expected to be observed on the protein level in adipose and other tissues as well as in macrophages and foam cells.\r\nObjective: To elucidate the underlying regulatory, compensatory and pathogenic mechanisms of lipid accumulation on the proteome level.\r\nProteins interacting with recently identified lipases, as well as lipid droplet-associated proteins, which might regulate substrate accessibility, will be isolated from tissue fractions or cell lines, identified by LC-MS and analyzed for the presence of isomers and post-translational modifications, especially phosphorylation. Related tissue/cell fractions or immunoprecipitations will be profiled with respect to protein abundance by DIGE and/or isotopic labelling and LC-MS. Selected proteins will be confirmed by Western blotting. Phosphoproteomics and activity-based proteomics will be applied as described in Project 1.\r\n","en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":28394,"category":10,"type":10,"partner_function":2,"manager":58794,"contact":58794,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2654-58794-10"]},{"id":1820,"title":{"de":"NANO-AS: Nano-Tox-Verlängerung","en":"NANO-AS: Nano-Tox-Verlängerung"},"short":"NANO-AS","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T12:36:34+02:00","program":null,"subprogram":"Nano-Health","organization":28394,"category":10,"type":10,"partner_function":2,"manager":53900,"contact":53900,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1820-53900-10"]}]}